Effect of cannabidiol on schizophrenia based on randomized controlled trials: A meta-analysis

文献类型： 外文期刊

第一作者： Zhang, Shuquan

作者： Zhang, Shuquan;Li, Min;Guo, Zhenhua

作者机构：

关键词： Antipsychotic; Cannabidiol; Brain; Genetics; Meta-analysis; Schizophrenia; Symptom; Treatment

期刊名称：ANNALES MEDICO-PSYCHOLOGIQUES （ 影响因子：0.504； 五年影响因子：0.371 ）

ISSN： 0003-4487

年卷期： 2022 年 180 卷 7 期

页码：

收录情况： SCI

摘要： Studies and treatments of schizophrenia with cannabidiol (CBD) alone have been reported. However, there have been a variety of different results of the effects of CBD in schizophrenic patients based on the positive and negative syndrome scale (PANSS). Thus, the present meta-analysis aimed to determine the effects of CBD on schizophrenia. We searched internet databases and identified 774 potentially relevant studies, among which nine studies were ultimately included in our present meta-analysis. Our results showed that CBD treatments significantly decreased PANSS positive scores (95% CI,-2.51,-0.89, P = 0.27, I-2 = 18%) but had no effect on other PANSS scores. Interestingly, while the safety of CBD has continued to be further demonstrated over time despite the dosage of CBD being gradually increased, the dosage of delta-9-tetrahydrocannabinol (THC) has remained essentially unchanged. Following our present meta-analysis, we suggest possible mechanisms of CBD-based amelioration of schizophrenic symptoms, such as CBD-induced increases in fronto-striato-thalamic coupling. (C) 2021 Elsevier Masson SAS. All rights reserved.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序